Histone demethylase KDM3B protects against ferroptosis by upregulating SLC7A11

Yishu Wang¹, Yao Zhao¹, Haihua Wang¹, Chengliang Zhang², Meiqi Wang², Yong Yang¹, Xin Xu¹,² and Zhenbo Hu¹

1 Laboratory for Stem Cell and Regenerative Medicine, The Affiliated Hospital of Weifang Medical University, Weifang, China
2 College of Bioscience and Technology, Weifang Medical University, Shandong, China

Keywords
ATF4; ferroptosis; histone; histone demethylase; KDM3B; SLC7A11

Correspondence
Z. Hu and X. Xu, Laboratory for Stem Cell and Regenerative Medicine, the Affiliated Hospital of Weifang Medical University, China
Fax: +86 536 8650309
Tel: +86 536 2602261 (ZH); +86 536 2602261 (XX)
E-mail: huzhenbo@wfmc.edu.cn (ZH); xinxu@wfmc.edu.cn (XX)

(Received 20 January 2020, revised 17 February 2020, accepted 25 February 2020)
doi:10.1002/2211-5463.12823

Ferroptosis is a type of adaptive cell death driven by cellular metabolism and iron-dependent lipid peroxidation. Though multiple genes (including SLC7A11 and GPX4) have been demonstrated to play key roles in ferroptosis, little is known about the epigenetic regulation of this process. Here, we report that KDM3B, a histone H3 lysine 9 demethylase, can protect against ferroptosis induced by Erastin, an inhibitor of SLC7A11. KDM3B overexpression in HT-1080 cells results in decreased histone H3 lysine 9 methylation. Furthermore, KDM3B upregulates the expression of SLC7A11 through cooperation with the transcription factor ATF4. In summary, we identify here KDM3B as a potential epigenetic regulator of ferroptosis.

Ferroptosis is a newly discovered form of regulated cell death characterized morphologically by the abnormal mitochondria structure and mechanically by the iron-dependent accumulation of lipid hydroperoxides to lethal concentrations [1]. Ferroptosis dysfunctions have been demonstrated to be associated with multiple physiological and pathological processes, including cancer cell death, neurotoxicity, neurodegenerative diseases, acute renal failure, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, and T-cell immunity. A large number of genes play essential roles in ferroptosis. For example, glutathione peroxidase 4 (GPX4) functions as a negative regulator of ferroptosis by limiting ROS production. SLC7A11, a specific light-chain subunit of the cystine/glutamate antiporter, also plays a negative role in ferroptosis. Thus, ferroptosis can be activated by SLC7A11 inhibition with the use of Erastin or by GPX inhibition with the use of Ras-selective lethal small molecule 3 (RSL3) [2,3].

Few details are known about the epigenetic regulation of ferroptosis. Lymphoid-specific helicase (LSH), a DNA modifier, interacts with WDR76 to suppress ferroptosis by inducing lipid metabolism-associated genes such as GLUT1- and ferroptosis-related genes SCD1 and FADS2 [4]. A nuclear deubiquitinating enzyme, BAP1, represses SLC7A11 expression by decreasing H2A ubiquitination occupancy on the SLC7A11 promoter leading to elevated lipid peroxidation and in turn ferroptosis [5]. H2B ubiquitination, on the other hand, is an epigenetic marker for SLC7A11 expression regulated by p53 [6]. Moreover, (+)-JQ1, a BET family inhibitor, regulates

Abbreviations
AML, acute myeloid leukemia; GPX4, glutathione peroxidase 4; RSL3, Ras-selective lethal small molecule 3.
ferritinophagy and the expression of ferroptosis-associated genes by epigenetically inhibiting BRD4 through suppression of the histone methyltransferase G9a or activation of the histone deacetylase SIRT1 [7].

Here, we reported the regulation of ferroptosis by histone demethylase KDM3B. KDM3B confers resistance to Erastin-induced ferroptosis by activating the expression of SLC7A11, a key player of ferroptosis. Thus, we can surmise KDM3B as a new ferroptosis-associated gene.

**Materials and methods**

**Reagents and human cell lines**

Erastin was purchased from Sigma (Shanghai, China), RSL3 was purchased from Selleckchem (Shanghai, China), and KDM3B inhibitor JDI-16 was purchased from Topscience (Shanghai, China).

Human cell lines used in this study (HT-1080, catalog number #ACC16, 293, catalog number #ACC305, and THP-1, catalog number #ACC315) are held by the Leibniz-Institute DSMZ-German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). Cells were cultured using the recommended culture conditions (https://www.dsmz.de/). All cells were authenticated using the standard STR (short tandem repeats) genotyping method (ANSI/ATCC ASN-0002-2011) [8].

**Transient and stable transfection**

The plasmids containing the CDS region of KDM3B (described previously [9]) and JMJD1C (kindly provided by Kristian Helin [10]) were inserted into pMCN-GFP-vector to construct pMCN-GFP-KDM3B/puromycin and pMCN-GFP-JMJD1C/puromycin, respectively. KDM3B siRNA was purchased from Qiagen (Shanghai, China).

Transient transfection of plasmids and siRNA was performed using Lipofectamine 2000 (Invitrogen, Shanghai, China) per the manufacturer’s protocol. Stable transfection was performed as shown below. High viability cells were seeded at 2 × 10^5 in 10 mL Dulbecco’s modified Eagle’s medium/10% FBS for single clone isolation on tissue culture dishes. After 16 h, the medium was reduced to 5 mL and transfected with the following superfect (Qiagen) protocol. 5 µg of each plasmid was used. The HT-1080 and 293 cells were selected after a further 24 h with 0.4 µg/mL puromycin (Invitrogen). After 14 days, the first puromycin-resistant single clones should become visible.

**Cell proliferation assay**

HT-1080 and 293 cells were plated at the seeding density of 2000/mL in 100 µL medium in 96-well plates. Chemicals were added after 24 h. Suspension cells THP-1 were plated at the seeding density of 4000/mL in 100 µL medium in 96-well round-bottom plates, and chemicals were added after 24 h. Plates were incubated for 2–4 days at 37 °C in 5% CO2. Cells were then lysed with ViaLight Plus kit (Lonza, Cologne, Germany) according to the manufacturer’s protocol, and a chemiluminescent signal was detected with a TECAN Spark 10M microplate reader (Crailsheim, Germany).

**Western blotting**

Total cellular proteins isolated from parental HT-1080 and KDM3B overexpressed HT-1080 were run on 15% SDS/PAGE for electrophoresis. Antihistone H3 (#06-755; Millipore, Darmstadt, Germany) and anti-H3K9-mel (#07-450; Millipore) antibodies were used for primary detection. As secondary antibodies, either anti-rabbit or anti-mouse IgG conjugated with horseradish peroxidase (HRP; GE Healthcare, Braunschweig, Germany) was used. Western Lightning Plus ECL (Perkin Elmer, Waltham, MA, USA) reagents were used for fluorescence production and AL600 (GE Healthcare, Shanghai, China) was used for fluorescence detection to visualize the proteins detected.

**Quantitative PCR**

One million cells were collected for RNA isolation. Two micrograms of total RNA from HT-1080 and 293 was reverse-transcribed into cDNA using Invitrogen Superscript II reverse transcriptase (Life Technologies, Shanghai, China) according to the manufacturer’s instructions. Random primers were used to obtain cDNA. Synthesized cDNA served as the template in 20 µL qPCRs. qPCR was performed using SYBR protocols (Takara, Dalian, China). The PCR was run in an ABI7500 fast real-time PCR machine with qPCR cycling conditions of 95 °C for 30 s, followed by 40 cycles of 95 °C for 3 s and 60 °C for 30 s. Relative concentrations of each target template were calculated according to the comparative Ct method. Expression of target transcripts was standardized to GAPDH. qPCR analyses were performed in triplicate. Primers used are available upon request.

**Luciferase assay**

SLC7A11 promoter was cloned from blood cDNA of healthy donors as described previously [11] and was inserted into pGL3-enhancer plasmids (Promega, Madison, WI, USA). pRL-TK (Promega) was used as control plasmid. Luciferase and renilla activities were detected using Promega Dual-Luciferase Reporter Assay System. The assay was finished in Sirius L Tube luminometer (Berthold Detection Systems, Pforzheim, Germany).
Statistical analysis

Quantitative results are reported as mean ± standard deviation (SD). The statistical analysis of cell proliferation, qPCR, and luciferase assays was performed using Student’s t-test. Comparisons with a P value ≤ 0.05 were considered statistically significant.

Results and Discussion

Overexpressed KDM3B prevents cells from Erastin-induced ferroptosis

Though very little is known about the epigenetic regulation of ferroptosis, we have been working on histone H3 lysine 9 demethylases KDM3B in hope of elucidating its mysteries. Our RNA sequencing results showed that potential inhibitors of KDM3B regulate ferroptosis-associated genes, especially SLC7A11 [12]. We postulated that KDM3B and its family member JMJD1C may be involved in ferroptosis. HT-1080 is a classical cell line for ferroptosis research, and we stably expressed ectopic KDM3B in HT-1080 cells. We then treated HT-1080 cells overexpressing KDM3B with type I ferroptosis inducer Erastin and type II ferroptosis inducer RSL3. As shown in Fig. 1A, KDM3B overexpression in HT-1080 yields robust resistance to Erastin- but only modest resistance to RSL3-induced cell death. We also examined the effect of JMJD1C on Erastin-induced ferroptosis by using 293 cell line with stable JMJD1C overexpression. As shown in Fig. 1B, JMJD1C, a KDM3B family member, does not confer Erastin resistance. Since KDM3B is a histone demethylase, we also measured the effect of stably overexpressed KDM3B on the methylation modifications of histone H3 lysine 9. In contrast with transient enforced expression of KDM3B, stably overexpressed

![Fig. 1](image-url)
KDM3B showed no significant effect on H3K9 methylation levels (Fig. 1C). JMJD1C did not significantly change H3K9 methylation levels (Fig. 1D). The balanced histone methylation levels after stable transfection served as the prevailing explanation for the lack of differential H3K9 methylation detection. Another plausible reason is that KDM3B may catalyze other histone modifications reported previously [13] or non-histone substrates [14]. To sum up, we postulated that KDM3 family member KDM3B negatively regulates ferroptosis.

To further study the role of KDM3B in ferroptosis, we also measured the effect of KDM3B inhibitors on Erastin-induced cell proliferation repression in cells different from HT-1080. Yang et al. [2] examined the effect of Erastin on 117 cell lines and identified Erastin-sensitive and Erastin-insensitive cell lines. Notably, acute myeloid leukemia (AML) cells are insensitive to Erastin (AUC > 5.5, the area under the concentration-response curve). Since KDM3B has been shown to associate with AML [15,16], we treated Erastin-resistant AML cell line THP-1 (as reported by Yang et al.) with Erastin and KDM3B inhibitor JDI-16. As shown in Fig. 1E, JDI-16 synergized with Erastin to repress the cell proliferation of THP-1. These results showed that KDM3B inhibition could sensitize Erastin-resistant cancer cells for ferroptosis-associated cell death.

KDM3B activates the expression of SLC7A11

Since KDM3B confers robust resistance to Erastin and modest resistance to RSL3, we measured the mRNA changes of key ferroptosis-associated genes upon KDM3B overexpression. As shown in Fig. 2A–F, multiple ferroptosis-associated genes were affected by KDM3B overexpression in HT-1080 cells. Among them, SLC7A11 showed significant upregulation by enforced KDM3B, consistent with the results that

![Image]

Fig. 2. The transcriptional regulation of SLC7A11 by KDM3B. (A–F) The mRNA levels of indicated genes affected by KDM3B overexpression. Parental and KDM3B overexpressed HT-1080 cells were collected for RNA extraction and qPCR. GAPDH was used as an endogenous control. (G) The effect of enforced ATF4, p53, KDM3B, and the combination on the SLC7A11 promoter activities. The SLC7A11 promoter reporter along with ATF4, p53, and KDM3B plasmids was transfected into HT-1080 cells with pRL-TK as an endogenous control. (H) The effect of enforced ATF4 and KDM3B siRNA on the SLC7A11 promoter activities. The SLC7A11 promoter reporter along with ATF4 and KDM3B siRNA was transfected into HT-1080 cells with pRL-TK as an endogenous control. For (A–H), three independent experiments were performed, quantitative results are reported as mean ± SD, the statistical analysis was performed using Student’s t-test, and P value smaller than 0.05 (represented by *) was regarded as statistically significant.
KDM3B bestow much more resistance to Erastin than RSL3. Moreover, JMJD1C overexpression had no discernible effect on SLC7A11 expression (Fig. 3), consistent with the aforementioned results that JMJD1C overexpression does not lead to Erastin resistance. Considering that SLC7A11 mediates the effect of multiple chromatin-associated proteins including BAP1 and BRD4 on Erastin-induced ferroptosis [5,7], we thus postulated that KDM3B plays a role in the transcriptional regulation of SLC7A11.

Multiple transcriptional factors like ATF4 and p53 have been reported to positively and negatively regulate the expression of SLC7A11, respectively [3,17]. We measured the effect of KDM3B on the ATF4- or p53-dependent luciferase activities of SLC7A11 promoter. As shown in Fig. 2G, KDM3B cooperates with ATF4 to activate the SLC7A11 promoter, whereas KDM3B rescues SLC7A11 repression by p53. On the other hand, ATF4-activated elevation of SLC7A11 promoter activities could be attenuated by KDM3B knockdown (Fig. 2H). KDM3B may function as a coregulator of ATF4 or p53 for SLC7A11 regulation. ATF4 has been shown to interact with another KDM family member KDM4C [18]. Additionally, ATF4 could be regulated by methylation catalyzed by PRMT1 [19]. P53 methylation has also been broadly reported for the determination of p53 function [20]. KDM3B may regulate SLC7A11 in a manner
KDM3B antagonizes ferroptosis

Y. Wang et al.

independent of histone demethylation, but dependent on the demethylation of nonhistone substrates like ATF4 and or p53.

KDM3B could also regulate Erastin-induced ferroptosis dependent on other genes such as VDAC3 and CARS [1]. Erastin has been reported to induce ferroptosis through directly binding to VDAC2/3 leading to the alternation of the permeability of the outer mitochondrial membrane and the decreases of the rate of NADH oxidation [21]. Loss of CARS, the cysteinyl-tRNA synthetase, blocks Erastin-induced ferroptosis [22]. Both VDAC3 and CARS function as positive regulators of ferroptosis [23] and KDM3B could confer ferroptosis resistance by downregulating VDAC3 and CARS as shown in Fig. 2.

In conclusion, we reported the regulation of ferroptosis by KDM3B (Fig. 4). Further study of KDM3B regulation of ferroptosis in leukemia is merited.

Acknowledgements

The research was supported by the National Natural Science Foundation of China (NSFC) grants (#81370628, #81570157), the Alexander von Humboldt Foundation, the Scientific Research Foundation for the Returned Overseas Chinese Scholars State Education Ministry, Shandong Provincial Natural Science Foundation, China (#ZR2015CL023), Shandong Province Higher Educational Science and Technology Program (J16LL54), and Weifang Science and Technology Development Plan (2018GX079). We thank Dr. Wilhelm Dirks and Silke Faehnrich for constructing stable transfection cell lines. We thank Ms. Linda Hu for helping in English editing.

Conflicts of interest

All authors declare no conflict of interest.

Author contributions

WY performed most experiments and drafted figures. ZY performed cell culture; WH performed cell proliferation detection. ZC and WM performed Western blotting. YY performed qPCR. XX supervised the project and drafted the manuscript. HZ supervised the project and modified the manuscript.

References

1 Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK, Kagan VE et al. (2017) Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273–285.
2 Yang WS, Sriramaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemens PA, Shamji AF, Clish CB et al. (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331.
3 Jiang L, Kon N, Li T, Wang S-J, Su T, Hibschoosh H, Baer R and Gu W (2015) Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57–62.
4 Jiang Y, Mao C, Yang R, Yan B, Shi Y, Liu X, Lai W, Liu Y, Wang X, Xiao D et al. (2017) EGLN1/c-Myc induced lymphoid-specific helicase inhibits ferroptosis through lipid metabolic gene expression changes. Theranostics 7, 3293–3305.
5 Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, Sirohi K, Li X, Wei Y, Lee H et al. (2018) BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol 20, 1181–1192.
6 Wang Y, Yang L, Zhang X, Cui W, Liu Y, Sun Q, He Q, Zhao S, Zhang G, Wang Y et al. (2019) Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53. EMBO Rep 20, e47563.
7 Sui S, Zhang J, Xu S, Wang Q, Wang P and Pang D (2019) Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells. Cell Death Dis 10, 331.
8 Dirks W, MacLeod RA, jäger K, Milch H and Drexler HG (1999) First searchable database for DNA profiles of human cell lines: sequential use of fingerprint techniques for authentication. Cell Mol Biol 45, 841–853.
9 Xu X, Nagel S, Quentinmeier H, Wang Z, Pommerenke C, Dirks WG, Macleod RAF, Drexler HG and Hu Z (2018) KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia. Leuk Lymphoma 59, 204–213.
10 Sroczynska P, Cruickshank VA, Bukowski JP, Miyagi S, Bagger FO, Walfridsson J, Schuster MB, Porse B and Helin K (2014) ShRNA screening identifies JMJD1C as being required for leukemia maintenance. Blood 123, 1870–1882.
11 Ye P, Mimura J, Okada T, Sato H, Liu T, Maruyama A, Ohyama C and Ihoh K (2015) Correction for Ye et al.,Correction for Ye upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol Cell Biol 35, 2366–2366.
12 Xu X, Wang L, Hu L, Dirks WG, Zhao Y, Wei Z, Chen D, Li Z, Wang Z, Han Y et al. (2020) Small molecular modulators of JMJD1C preferentially inhibit growth of leukemia cells. Int J Cancer 146, 400–412.
13 Li S, Ali S, Duan X, Liu S, Du J, Liu C, Dai H, Zhou M, Zhou L, Yang L et al. (2018) JMJD1B demethylates H4R3me2s and H3K9me2 to facilitate gene expression
for development of hematopoietic stem and progenitor cells. Cell Rep 23, 389–403.

14 Watanabe S, Watanabe K, Akimov V, Bartkova J, Blagoev B, Lukas J and Bartek J (2013) JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks. Nat Struct Mol Biol 20, 1425–1433.

15 Hu Z, Gomes I, Horrigan SK, Kravarusic J, Mar B, Arbieva Z, Chyna B, Fulton N, Edassery S, Raza A and et al. (2001) A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31. Oncogene 20, 6946–6954.

16 Kim J-Y, Kim K-B, Eom GH, Choe N, Kee HJ, Son H-J, Oh S-T, Kim D-W, Pak JH, Baek HJ et al. (2012) KDM3B is the H3K9 demethylase involved in transcriptional activation of Lmo2 in leukemia. Mol Cell Biol 32, 2917–2933.

17 Chen D, Fan Z, Rauh M, Buchfelder M, Eyupoglu IY and Savaskan N (2017) ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner. Oncogene 36, 5593–5608.

18 Zhao E, Ding J, Xia Y, Liu M, Ye B, Choi JH, Yan C, Dong Z, Huang S, Zha Y et al. (2016) KDM4C and ATF4 cooperate in transcriptional control of amino acid metabolism. Cell Rep 14, 506–519.

19 Yuniati L, van der Meer LT, Tijchon E, Schenau DI, van Emst L, Levers M, Palit SAL, Rodenbach C, Poelmans G, Hoogerbrugge PM et al. (2016) Tumor suppressor BTG1 promotes PRMT1-mediated ATF4 function in response to cellular stress. Oncotarget 7, 3128–3143.

20 Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M, Kessler B and La Thangue NB (2008) Arginine methylation regulates the p53 response. Nat Cell Biol 10, 1431–1439.

21 Yagoda N, Von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Smukste I, Peltier JM, Boniface JJ et al. (2007) RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447, 865–869.

22 Hayano M, Yang WS, Corn CK, Pagano NC and Stockwell BR (2016) Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Differ 23, 270–278.

23 Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R and Tang D (2016) Ferroptosis: process and function. Cell Death Differ 23, 369–379.